Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Xeris Biopharma Holdings Inc’s stock clocked out at $5.43, down -1.45% from its previous closing price of $5.51. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 3.76 million shares were traded.
Ratios:
To gain a deeper understanding of XERS’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.19 and its Current Ratio is at 1.67.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.Craig Hallum initiated its Buy rating on August 28, 2023, with a $4.50 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 20 ’25 when Hecht Beth bought 40,000 shares for $5.14 per share.
Schmid John P. bought 4,515 shares of XERS for $10,147 on Aug 12 ’24. The Director now owns 25,200 shares after completing the transaction at $2.25 per share. On Aug 09 ’24, another insider, Schmid John P., who serves as the Director of the company, bought 4,285 shares for $2.37 each. As a result, the insider paid 10,134 and bolstered with 20,685 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.12.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $5.53, while it has fallen to a 52-week low of $1.69. The 50-Day Moving Average of the stock is 41.68%, while the 200-Day Moving Average is calculated to be 76.57%.
Shares Statistics:
A total of 149.43M shares are outstanding, with a floating share count of 142.00M. Insiders hold about 7.76% of the company’s shares, while institutions hold 42.76% stake in the company.
